Dr Reddy’s Laboratories has announced the commercial launch of 2DG, an anti-COVID19 drug. The maximum retail price (MRP) of each sachet was set by the pharmaceutical company at Rs 990.
2-deoxy-D-glucose (2DG) is an oral antiviral drug for patients with Covid-19. The drug sparked a lot of curiosity after it was launched by the Department of Defense on May 17. It was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading DRDO laboratory, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad.
2-DG is 99.5% pure and will be marketed under the brand name 2DG.
Dr Reddy’s will supply drugs to state governments as well as private hospitals across the country. The company will make the drug available in hospitals in major and first-tier cities in the first weeks, and then expand its coverage to the rest of India.
The pharmaceutical major said that in the first week of June he launched the serial production of the drug. The drug will be provided to the state at a reduced price.
Medicines General of India (DGCI) has approved an oral emergency drug as adjunctive therapy for the treatment of patients with severe Covid.
According to the Ministry of Defense, the drug has shown in clinical trials that it promotes faster recovery in hospitalized patients with Covid and reduces dependence on supplemental oxygen. A higher proportion of patients receiving 2-DG showed negative RT-PCR conversion in COVID patients.
In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the Center for Cellular and Molecular Biology (CCMB) in Hyderabad and found that the molecule was effective against the SARS-CoV-2 virus and suppressed viral growth.